{
  "docId": "019de076-f497-7249-9bc1-6e417e62b814",
  "docSlug": "fb4563ff56b082126dc8200b1dba24d8",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 23 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 23,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a two-column layout: the left side focuses on the disease burden and market opportunity, while the right side details the therapeutic solution and its mechanism of action.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f497-7249-9bc1-6e417e62b814/13",
  "deckHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814",
  "deckJsonHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814.json",
  "deckAnchorHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.48,
        "x": 0.48,
        "y": 0.05
      },
      "kind": "callout",
      "text": "BEN-8744: Oral, peripherally-restricted, PDE10 inhibitor under development as a first-in-class treatment for refractory UC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0de40137-7f01-4616-9e7d-b9d6b24053e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "UC affects >1.9 million patients in 8MM, of which 31% have moderate-severe disease. Crohn's disease (CD) affects >1.6 million patients in 8MM, 41% of US patients have moderate disease.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c6b8f4a-b18f-4ac2-9b11-f2eee796ced2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Chronic, lifelong inflammation; UC market forecast of $10.7bn and CD forecast of $18.4bn in 2028; 20-40% of patients do not respond to anti-TNF; current treatments have many side effects; high unmet need.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "401f0b36-b463-4575-b352-eb544925bb09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.5,
        "y": 0.25
      },
      "kind": "list",
      "text": "PDE10 identified by TargetID; Molecular Design expertise; efficacious disease modifying oral treatment; targets moderate/severe patients; addresses refractory patients and safety concerns.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b018e31-ea1a-4c10-8389-dd29e64ece0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Sources: (1) GlobalData: Ulcerative Colitis... (6) US FDA Drug Safety Communication 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b1ba22a-745a-419a-8285-d065678f25ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "BEN-8744 Ulcerative Colitis (UC)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a99d6d8a-7593-4be9-8c3c-6f7c4b2173a1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 8,
      "beatId": "f2ab71c9-53f6-440d-9d03-02e61c9ddb19",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Discussion of pipeline progression, strategic collaborations, and financial highlights",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "423b3a2a-1477-48ad-8005-2c65d02aa02b",
      "evidence": "Problem statement and key messages about BEN-8744",
      "position": 0,
      "objective": "Highlighting the need for BEN-8744 in ulcerative colitis treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 23,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b0e19ace-ba0d-475a-81b8-bb29008de35f",
      "evidence": "The deck's overall narrative and key takeaways",
      "position": 1,
      "objective": "Communicating the why, how, and what of BenevolentAI's AI-driven drug discovery",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}